2
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Neoplasms
5
Colorectal Neoplasms, Hereditary Nonpolyposis
3
Colorectal Neoplasms
3
Sarcoma
2
Recurrence
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Stage IIIb and IV Non Small Cell Lung Cancer
1
Solid Tumor, Adult
1
Rare Diseases
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplastic Syndromes, Hereditary
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Microsatellite Instability
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hereditary Breast and Ovarian Cancer Syndrome
1
Head and Neck Neoplasms
1
Genetic Predisposition to Disease
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Medullary
1
COVID-19
1
Biliary Tract Neoplasms
1
Interventions
Dexamethasone
808
Bortezomib
446
Lenalidomide
430
Cyclophosphamide
336
Melphalan
250
Calcium Dobesilate
236
daratumumab
217
pomalidomide
201
carfilzomib
181
fludarabine phosphate
131
Thalidomide
121
fludarabine
118
Peripheral Blood Stem Cell Transplantation
117
Filgrastim
111
ixazomib
85
Mycophenolic Acid
85
Granulocyte Colony-Stimulating Factor
84
Busulfan
83
Whole-Body Irradiation
80
Tacrolimus
75
dexamethasone acetate
74
Cyclosporine
67
Prednisone
64
dexamethasone 21-phosphate
63
isatuximab
62
elotuzumab
60
auricularum
57
Antilymphocyte Serum
55
belantamab mafodotin
54
Etoposide
52
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Multiple Myeloma
×
High-Throughput Nucleotide Sequencing
×
Clear all
NCT05013437
2024-04-02
AHCT
Case Comprehensive Cancer Center
Phase EARLY_PHASE1
Withdrawn